As of 2024-12-14, the Intrinsic Value of Foghorn Therapeutics Inc. (FHTX) is
16.51 USD. This FHTX valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y).
With the current market price of 5.30 USD, the upside of Foghorn Therapeutics Inc. is
211.60%.
The range of the Intrinsic Value is 14.17 - 18.97 USD
16.51 USD
Intrinsic Value
FHTX Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(257.61) - (54.87) |
(87.95) |
-1759.5% |
| DCF (Growth 10y) |
(41.01) - (165.23) |
(61.38) |
-1258.2% |
| DCF (EBITDA 5y) |
14.17 - 18.97 |
16.51 |
211.6% |
| DCF (EBITDA 10y) |
12.37 - 19.48 |
15.77 |
197.5% |
| Fair Value |
-8.21 - -8.21 |
-8.21 |
-254.81% |
| P/E |
(27.24) - (28.39) |
(23.59) |
-545.1% |
| EV/EBITDA |
(24.62) - (25.48) |
(24.71) |
-566.2% |
| EPV |
(19.95) - (24.33) |
(22.14) |
-517.7% |
| DDM - Stable |
(15.70) - (51.59) |
(33.65) |
-734.8% |
| DDM - Multi |
(9.49) - (24.27) |
(13.65) |
-357.5% |
FHTX Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
294.63 |
| Beta |
3.26 |
| Outstanding shares (mil) |
55.59 |
| Enterprise Value (mil) |
236.95 |
| Market risk premium |
4.60% |
| Cost of Equity |
9.09% |
| Cost of Debt |
5.00% |
| WACC |
6.38% |